Biosimilars present a necessary and timely opportunity for physicians, patients and
healthcare systems. If suitably developed clinically, manufactured to the correct standards …

Biosimilars, based on biopharmaceuticals approved by regulatory agencies that are no
longer under patent protection, have efficacy and safety comparable to their reference …

Psoriasis is a chronic, inflammatory, lifelong disease with a high prevalence (afflicting
approximately 1–5% of the population worldwide) and is associated with significant …

Biologics are vital to the management of patients with rheumatic and musculoskeletal
diseases such as rheumatoid arthritis and other inflammatory and autoimmune conditions …

The introduction of biological drugs for the treatment of patients with psoriasis has
revolutionized treatment paradigms and enabled numerous patients to achieve disease …

Objectives To discuss current terminology and the regulatory standards and processes
involved in the development of biosimilars. Methods An Internet-based literature search …

Biosimilars are copies of reference biological drugs, developed as the patents for original
biologicals expire. They are thus developed to replicate an original biological medicine just …

Healthcare systems worldwide are struggling to find ways to fund the cost of innovative
treatments such as gene therapies, regenerative medicine, and monoclonal antibodies …

Objectives Previous studies demonstrated equivalence in terms of efficacy and safety of
biosimilars (bsDMARDs) compared to original treatments (boDMARDs) and in switching …

A biosimilar is an officially regulated and approved copy of an originator biologic therapy.
Improved affordability and consequent wider patient access compared with biologics are a …